Equities analysts predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report sales of $49.80 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $48.40 million and the highest estimate coming in at $51.00 million. Vanda Pharmaceuticals reported sales of $41.34 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.5%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $193.00 million for the current fiscal year, with estimates ranging from $189.00 million to $196.00 million. For the next financial year, analysts anticipate that the firm will report sales of $237.77 million per share, with estimates ranging from $223.00 million to $261.30 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.14. The firm had revenue of $47.40 million for the quarter, compared to the consensus estimate of $47.28 million. Vanda Pharmaceuticals had a return on equity of 0.68% and a net margin of 0.73%. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS.

A number of research firms recently issued reports on VNDA. BidaskClub upgraded Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 21st. Oppenheimer set a $27.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Stifel Nicolaus began coverage on Vanda Pharmaceuticals in a research note on Thursday, September 13th. They set a “buy” rating and a $30.00 price target on the stock. Seaport Global Securities restated a “buy” rating and set a $26.00 price target on shares of Vanda Pharmaceuticals in a research note on Thursday, August 2nd. Finally, Citigroup began coverage on Vanda Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $26.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $25.50.

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Vanda Pharmaceuticals during the 1st quarter worth approximately $117,000. Trexquant Investment LP acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $212,000. Hartford Investment Management Co. acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $214,000. NumerixS Investment Technologies Inc lifted its position in Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 5,700 shares during the period. Finally, Xact Kapitalforvaltning AB acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $240,000. 93.56% of the stock is owned by institutional investors.

NASDAQ:VNDA traded up $0.35 during mid-day trading on Thursday, reaching $19.45. 584,700 shares of the stock were exchanged, compared to its average volume of 587,057. The company has a market capitalization of $1.04 billion, a PE ratio of -55.57 and a beta of 0.52. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $23.35.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: Should I follow buy, hold and sell recommendations?

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.